Cart
sales@molnova.com
GSK 635416A
CAS No. 944729-29-7
GSK 635416A( GSK635416A )
Catalog No. M16767 CAS No. 944729-29-7
GSK 635416A is a novel ATM inhibitor with highly selective radiosensitizing activity, inhibits radiation induced phosphorylation of ATM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGSK 635416A
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK 635416A is a novel ATM inhibitor with highly selective radiosensitizing activity, inhibits radiation induced phosphorylation of ATM.
-
DescriptionGSK 635416A is a novel ATM inhibitor with highly selective radiosensitizing activity, inhibits radiation induced phosphorylation of ATM; exhibits virtually no cytotoxicity in the absence of radiation and in normal fibroblast cells, enhances IR effect in radiosensitizing HNSCC cell lines but not in normal fibroblast BJ-ET cells in combined with olaparib.
-
In Vitro——
-
In Vivo——
-
SynonymsGSK635416A
-
PathwayCell Cycle/DNA Damage
-
TargetATM/ATR
-
RecptorATM/ATR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number944729-29-7
-
Formula Weight453.532
-
Molecular FormulaC24H24FN3O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name2-amino-5-(4-fluorophenyl)-N-methyl-3-(4-pyrrolidin-1-ylsulfonylphenyl)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dohmen AJC, et al. Oncotarget. 2017 May 19;8(43):73925-73937.
molnova catalog
related products
-
KU-60019
KU-60019 is an improved analogue of KU-55933, and is a potent, specific inhibitor of ATM kinase with IC50 of 6.3 nM, 270- and 1,600-fold selectivity over DNA-PKcs and ATR.
-
CBP-93872
A potent G2 checkpoint inhibitor that specifically abrogates the DNA double-stranded break (DSB)-induced G2 checkpoint.
-
Camonsertib
Camonsertib (RP-3500) is a novel, potent and selective ATR kinase inhibitor (ATRi) that exhibits potent antitumor effects with an IC50: 1.00 nM in biochemical assays.
